A detailed history of Avantax Advisory Services, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 3,325 shares of NBIX stock, worth $454,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,325
Previous 2,112 57.43%
Holding current value
$454,294
Previous $233,000 78.97%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

BUY
$87.54 - $128.18 $106,186 - $155,482
1,213 Added 57.43%
3,325 $417,000
Q1 2025

May 06, 2025

SELL
$107.22 - $153.29 $83,953 - $120,026
-783 Reduced 27.05%
2,112 $233,000
Q4 2024

Feb 07, 2025

BUY
$111.62 - $139.44 $33,151 - $41,413
297 Added 11.43%
2,895 $395,000
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $23,030 - $30,783
-201 Reduced 7.18%
2,598 $299,000
Q2 2024

Aug 09, 2024

BUY
$130.86 - $143.19 $366,277 - $400,788
2,799 New
2,799 $385,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.